Document is current
Any future updates will be listed below
-
Authors
Ruppel, Richard https://orcid.org/0009-0002-7081-0300
Lindholz, Maximilian https://orcid.org/0000-0003-3690-1161
Schmidt, Robin https://orcid.org/0000-0003-0012-2799
El-Nahry, Yasmin https://orcid.org/0000-0001-6390-0143
Mechsner, Sylvia https://orcid.org/0000-0002-1095-0048
Schulze-Weddige, Sophia Elisabeth Ellen https://orcid.org/0000-0003-4248-5563
Baumgärtner, Georg Lukas https://orcid.org/0000-0003-3046-0019
Arlt, Tillmann https://orcid.org/0009-0008-5423-751X
Hamm, Charlie Alexander https://orcid.org/0000-0003-4104-4758
Arndt, Sebastian https://orcid.org/0009-0004-3445-0023
Siegler, Lisa
Stepansky, Leonard https://orcid.org/0009-0003-4590-9023
Hutter, Jana https://orcid.org/0000-0003-3476-3500
May, Matthias https://orcid.org/0000-0002-2540-850X
Penzkofer, Tobias https://orcid.org/0000-0001-9591-8575
- License Information
-
More Information
Chapter History
First Online: 24 September 2025
Disclosure of Interests
: M.L. receives funding from the Berlin Institute of Health (Junior Digital Clinician Scientist Grant). C.A.H. receives funding from the Berlin Institute of Health (Digital Clinician Scientist Grant) and Siemens Healthineers and previously received seed funding from the University Medicine Greifswald and speaker fees from Siemens Healthineers, Bayer AG, Koelis AG, and Bracco Imaging Deutschland outside the submitted work. T.P. also receives funding from the Berlin Institute of Health (Advanced Clinician Scientist Grant, Platform Grant), the Ministry of Education and Research (BMBF, 01KX2121 (“NUM 2.0”, RACOON), 68GX21001A, 01ZZ2315D), the German Research Foundation (DFG, SFB 1340/2), and the European Union (H2020, CHAIMELEON: 952172, DIGITAL, EUCAIM:101100633). Furthermore, T.P. declares relationships with the following companies: research agreements (no personal payments) with AGO, Aprea AB, AR-CAGY-GINECO, Astellas Pharma Global Inc. (APGD), Astra Zeneca, Clovis Oncology, Inc., Holaira, Incyte Corporation, Karyopharm, Lion Biotechnologies, Inc., MedImmune, Merck Sharp & Dohme Corp, Millennium Pharmaceuticals, Inc., Morphotec Inc., NovoCure Ltd., PharmaMar S.A. and PharmaMar USA, Inc., Roche, Siemens Healthineers, and TESARO Inc.; fees for a book translation (Elsevier B.V.); and fees for speaking engagements (Bayer Healthcare).
Conference Information
Conference Acronym: DGM4MICCAI
Conference Name: MICCAI Workshop on Deep Generative Models
Conference City: Daejeon
Conference Country: Korea (Republic of)
Conference Year: 2025
Conference Start Date: 23 September 2025
Conference End Date: 23 September 2025
Conference Number: 5
Conference ID: dgm4miccai2025
Conference URL: https://dgm4miccai.github.io/
